These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1007 related articles for article (PubMed ID: 37166054)
1. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2. Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054 [TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP mBio; 2021 Mar; 12(2):. PubMed ID: 33785634 [TBL] [Abstract][Full Text] [Related]
3. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study. Shahbazi B; Mafakher L; Teimoori-Toolabi L J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180 [TBL] [Abstract][Full Text] [Related]
4. An Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364 [TBL] [Abstract][Full Text] [Related]
5. Withanone from Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804 [TBL] [Abstract][Full Text] [Related]
6. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents. Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269 [TBL] [Abstract][Full Text] [Related]
7. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective. Borkotoky S; Dey D; Hazarika Z Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937 [TBL] [Abstract][Full Text] [Related]
8. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms. Ali A; Vijayan R Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162 [TBL] [Abstract][Full Text] [Related]
9. Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay. Xiang Y; Zhai G; Li Y; Wang M; Chen X; Wang R; Xie H; Zhang W; Ge G; Zhang Q; Xu Y; Caflisch A; Xu J; Chen H; Chen L Int J Biol Macromol; 2023 Jan; 226():780-792. PubMed ID: 36521705 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19). Nayak SK Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074 [TBL] [Abstract][Full Text] [Related]
11. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937 [TBL] [Abstract][Full Text] [Related]
13. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2. Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310 [TBL] [Abstract][Full Text] [Related]
14. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
15. Biosensor-based active ingredient recognition system for screening potential small molecular Severe acute respiratory syndrome coronavirus 2 entry blockers targeting the spike protein from Rugosa rose. Yu W; Yi SZ; Jiang CY; Guan JW; Xue R; Zhang XX; Zeng T; Tang H; Chen W; Han B Biomed Chromatogr; 2024 Oct; 38(10):e5987. PubMed ID: 39126351 [TBL] [Abstract][Full Text] [Related]
16. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
17. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770 [TBL] [Abstract][Full Text] [Related]
18. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175 [TBL] [Abstract][Full Text] [Related]
19. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries. David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A Molecules; 2021 May; 26(11):. PubMed ID: 34072087 [TBL] [Abstract][Full Text] [Related]
20. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. Lata S; Akif M J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]